ZA967887B - Aerosol compositions - Google Patents
Aerosol compositionsInfo
- Publication number
- ZA967887B ZA967887B ZA967887A ZA967887A ZA967887B ZA 967887 B ZA967887 B ZA 967887B ZA 967887 A ZA967887 A ZA 967887A ZA 967887 A ZA967887 A ZA 967887A ZA 967887 B ZA967887 B ZA 967887B
- Authority
- ZA
- South Africa
- Prior art keywords
- liquefied hydrofluoroalkane
- fatty acid
- active ingredient
- medium
- chain fatty
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000005828 hydrofluoroalkanes Chemical class 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000004667 medium chain fatty acids Chemical class 0.000 abstract 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
- 238000001816 cooling Methods 0.000 abstract 1
- 239000002270 dispersing agent Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23934295 | 1995-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA967887B true ZA967887B (en) | 1997-04-07 |
Family
ID=17043318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA967887A ZA967887B (en) | 1995-09-19 | 1996-09-18 | Aerosol compositions |
Country Status (16)
Country | Link |
---|---|
US (2) | US6361760B1 (de) |
EP (1) | EP0851753B1 (de) |
JP (2) | JP3266005B2 (de) |
KR (1) | KR100523754B1 (de) |
CN (1) | CN1137680C (de) |
AT (1) | ATE254450T1 (de) |
AU (1) | AU719613B2 (de) |
CA (1) | CA2232378C (de) |
DE (1) | DE69630798T2 (de) |
DK (1) | DK0851753T3 (de) |
ES (1) | ES2206590T3 (de) |
HK (1) | HK1017845A1 (de) |
PT (1) | PT851753E (de) |
TW (1) | TW429153B (de) |
WO (1) | WO1997010806A1 (de) |
ZA (1) | ZA967887B (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998041191A1 (fr) * | 1997-03-14 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Preparation pour aerosol |
GB0012383D0 (en) * | 2000-05-22 | 2000-07-12 | Novartis Ag | Organic compounds |
US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
US6943267B1 (en) | 2001-08-24 | 2005-09-13 | Utah State University | Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases |
MXPA04011851A (es) * | 2002-05-30 | 2005-03-31 | Celgene Corp | Metodos para utilizar inhibidores de jnk o mkk para modular diferenciacion de celula y para tratar desordenes mieloproliferativos y sindromes mielodispl??sticos. |
WO2004027027A2 (en) | 2002-09-18 | 2004-04-01 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
AU2002952559A0 (en) * | 2002-11-08 | 2002-11-21 | Fujisawa Pharmaceutical Co., Ltd. | New use |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
US20040230272A1 (en) * | 2003-04-11 | 2004-11-18 | Cates Adam W. | Subcutaneous lead with temporary pharmacological agents |
WO2004110335A1 (ja) * | 2003-06-10 | 2004-12-23 | Astellas Pharma Inc. | マクロライド系化合物を含有するエアゾール組成物が封入容器に封入されたエアゾール製剤 |
CN1882338A (zh) * | 2003-09-18 | 2006-12-20 | 马库赛特公司 | 经巩膜递送 |
BRPI0416266A (pt) * | 2003-11-06 | 2007-01-09 | Celgene Corp | método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente |
TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
CA2552305A1 (en) * | 2003-12-30 | 2005-07-14 | Astellas Pharma Inc. | Use of macrolides for treating or preventing airflow obstruction |
CA2588558A1 (en) * | 2004-11-23 | 2006-06-01 | Celgene Corporation | Jnk inhibitors for treatment of cns injury |
US20060258698A1 (en) * | 2005-02-09 | 2006-11-16 | Sreenivasu Mudumba | Liquid formulations for treatment of diseases or conditions |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
US8053569B2 (en) | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
US8492400B2 (en) | 2006-02-09 | 2013-07-23 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
JP5506378B2 (ja) | 2006-03-23 | 2014-05-28 | 参天製薬株式会社 | 血管透過性に関連する疾患または病気のための製剤および方法 |
AU2007285763B2 (en) | 2006-08-18 | 2011-12-15 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
EP2124898B1 (de) | 2007-01-10 | 2013-08-14 | Board of Regents, The University of Texas System | Verstärkte freisetzung immunsuppressiver arzneizusammensetzungen zur pulmonalen verabreichung |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
US20090011040A1 (en) * | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
US8974791B2 (en) * | 2007-07-27 | 2015-03-10 | Armagen Technologies, Inc. | Methods and compositions for increasing α-L-iduronidase activity in the CNS |
US20100098693A1 (en) * | 2008-10-07 | 2010-04-22 | Pardridge William M | Compositions and methods for blood-brain barrier delivery of organophosphatases |
WO2010052466A2 (en) * | 2008-11-04 | 2010-05-14 | Cipla Limited | Pharmaceutical aerosol composition |
JP5873003B2 (ja) | 2009-03-18 | 2016-03-01 | アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. | IgGデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法 |
HUE044865T2 (hu) | 2009-10-09 | 2019-11-28 | Armagen Inc | Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére |
DK2501716T3 (en) | 2009-11-19 | 2015-04-07 | Solis Biodyne Oü | Formations to increase polypeptidstabilitet and activity and related practices |
US20110318277A1 (en) * | 2010-06-25 | 2011-12-29 | APT Pharmaceuticals, Inc. University of Maryland, Baltimore | Tacrolimus compositions for aerosol administration |
EP4338797A3 (de) | 2011-12-02 | 2024-06-12 | Armagen, Inc. | Verfahren und zusammensetzungen zur erhöhung der arylsulfatase-a-aktivität im zns |
AU2014293626A1 (en) | 2013-07-22 | 2016-02-18 | Armagen, Inc. | Methods and compositions for increasing enzyme activity in the CNS |
US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
GB8608080D0 (en) | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
DK0406791T3 (da) | 1989-07-05 | 1995-03-27 | Fujisawa Pharmaceutical Co | Vandigt flydende præparat til ekstern anvendelse |
US5215995A (en) | 1989-10-16 | 1993-06-01 | Fujisawa Pharmaceutical Co., Ltd. | Hair revitalizing agent |
PH31204A (en) | 1990-11-02 | 1998-05-05 | Fujisawa Pharmaceutical Co | Pharmaceutical composition. |
IE65341B1 (en) | 1990-11-08 | 1995-10-18 | Fujisawa Pharmaceutical Co | Suspensions containing tricyclic compounds |
AU8910891A (en) * | 1990-11-20 | 1992-06-11 | National Heart & Lung Institute, The | Treatment of lung diseases |
US5817333A (en) * | 1991-10-31 | 1998-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Liposome preparation containing a tricyclic compound |
ES2134860T3 (es) | 1992-11-18 | 1999-10-16 | Fujisawa Pharmaceutical Co | Preparacion farmaceutica de accion prolongada. |
JPH06345646A (ja) | 1993-06-08 | 1994-12-20 | Fujisawa Pharmaceut Co Ltd | ローション剤 |
US5635161A (en) * | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
US5681501A (en) * | 1995-10-11 | 1997-10-28 | E. I. Du Pont De Nemours And Company | Compositions including a hydrofluoropropane |
WO1998041191A1 (fr) * | 1997-03-14 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Preparation pour aerosol |
CA2284988A1 (en) | 1997-04-11 | 1998-10-22 | Fujisawa Pharmaceutical Co., Ltd. | Medicinal composition |
-
1996
- 1996-09-18 US US09/029,863 patent/US6361760B1/en not_active Expired - Fee Related
- 1996-09-18 DE DE69630798T patent/DE69630798T2/de not_active Expired - Lifetime
- 1996-09-18 WO PCT/JP1996/002670 patent/WO1997010806A1/en active IP Right Grant
- 1996-09-18 ES ES96931227T patent/ES2206590T3/es not_active Expired - Lifetime
- 1996-09-18 PT PT96931227T patent/PT851753E/pt unknown
- 1996-09-18 AT AT96931227T patent/ATE254450T1/de not_active IP Right Cessation
- 1996-09-18 CA CA002232378A patent/CA2232378C/en not_active Expired - Fee Related
- 1996-09-18 DK DK96931227T patent/DK0851753T3/da active
- 1996-09-18 ZA ZA967887A patent/ZA967887B/xx unknown
- 1996-09-18 AU AU69998/96A patent/AU719613B2/en not_active Ceased
- 1996-09-18 KR KR1019980701910A patent/KR100523754B1/ko not_active IP Right Cessation
- 1996-09-18 CN CNB961981660A patent/CN1137680C/zh not_active Expired - Fee Related
- 1996-09-18 EP EP96931227A patent/EP0851753B1/de not_active Expired - Lifetime
- 1996-09-18 JP JP24605396A patent/JP3266005B2/ja not_active Expired - Lifetime
- 1996-09-18 JP JP51258997A patent/JP3362394B2/ja not_active Expired - Fee Related
- 1996-09-19 TW TW085111460A patent/TW429153B/zh not_active IP Right Cessation
-
1999
- 1999-05-07 HK HK99102062A patent/HK1017845A1/xx not_active IP Right Cessation
-
2001
- 2001-11-28 US US09/994,702 patent/US6524556B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1201384A (zh) | 1998-12-09 |
ES2206590T3 (es) | 2004-05-16 |
KR100523754B1 (ko) | 2007-06-04 |
DK0851753T3 (da) | 2004-03-15 |
TW429153B (en) | 2001-04-11 |
EP0851753B1 (de) | 2003-11-19 |
HK1017845A1 (en) | 1999-12-03 |
AU6999896A (en) | 1997-04-09 |
WO1997010806A1 (en) | 1997-03-27 |
JPH09143054A (ja) | 1997-06-03 |
DE69630798D1 (de) | 2003-12-24 |
CA2232378C (en) | 2009-04-14 |
KR19990044656A (ko) | 1999-06-25 |
JP2000505050A (ja) | 2000-04-25 |
US6361760B1 (en) | 2002-03-26 |
US6524556B2 (en) | 2003-02-25 |
ATE254450T1 (de) | 2003-12-15 |
CN1137680C (zh) | 2004-02-11 |
PT851753E (pt) | 2004-04-30 |
US20020061906A1 (en) | 2002-05-23 |
AU719613B2 (en) | 2000-05-11 |
JP3266005B2 (ja) | 2002-03-18 |
EP0851753A1 (de) | 1998-07-08 |
JP3362394B2 (ja) | 2003-01-07 |
CA2232378A1 (en) | 1997-03-27 |
DE69630798T2 (de) | 2004-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW429153B (en) | Aerosol compositions | |
AR021922A1 (es) | Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol. | |
ES2157307T3 (es) | Composicion topica que contiene un antagonista de sustancia p. | |
GB2062465B (en) | Topical preparation containing nitroglycerine and optionally other medicaments | |
CA2105575A1 (en) | Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions | |
NZ330369A (en) | aqueous medicaments containing 9-hydroxy-risperidone fatty acid ester | |
MX9606501A (es) | Composiciones antifungosas y curativas para heridas y metodos para preparar y utilizar las mismas. | |
NZ308293A (en) | Antibacterial-wound healing compositions comprising a pyruvate, antioxidant and fatty acids | |
MY119074A (en) | Pharmaceutical aerosol composition | |
MX9606502A (es) | Composiciones antiqueratoliticas y curativas para heridas y metodos para preparar y utilizar las mismas. | |
AR021921A1 (es) | Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido. | |
JPS5659710A (en) | Preventive and remedy for psoriasis | |
EP0147535A3 (de) | Pharmazeutische Zusammensetzung mit Gehalt an einem E-Prostaglandin, die als topisches Arzneimittel geeignet ist | |
AU1112395A (en) | Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide | |
AU3271795A (en) | Synergistic pharmaceutical compositions containing triamcinolone acetonide and halcinonide | |
EP0968713A4 (de) | Isosorbidnitrat enthaltentende pflaster | |
AU8740198A (en) | Inhibitor and preservative formulation | |
EP0966958A4 (de) | Aerosol-präparation | |
MY105086A (en) | Liquid detergent composition. | |
JPS6471439A (en) | Freshness retaining agent for fishes and shellfishes | |
ES456094A1 (es) | Un procedimiento para la preparacion de 2-acetoxi-benzoato de 2-(carbamoil) fenilo. | |
AU528211B2 (en) | Synergistic analgesic compositions of suprofen | |
LT2001072A (lt) | Maisto papildas | |
CA2066945A1 (en) | Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam | |
AU2989701A (en) | Pharmaceutical carrier composition for papayne based products |